 As device therapy continues to evolve, there is an emerging opportunity to address tricuspid valve disease in patients who previously were overlooked due to their high surgical risk. Proper patient selection and medical optimization will be critical factors driving the success or failure of these nascent technologies.     In this interview, Sean Pinney MD, FACC, FAST, FHFSA, and Sidney C. Smith Jr. MD, MACC, discuss "Optimal Medical Therapy for Tricuspid Regurgitation: An  Oxymoron?"     Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

ACCEL Lite: Optimal Medical Therapy for Tricuspid Regurgitation: An Oxymoron?

The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Health & Fitness

 The Be Active trial demonstrates the efficacy of scalable interventions, incorporating remote monitoring and behavioral economics, in boosting physical activity among high-risk cardiovascular patients. Lasting effects were observed even six months post-intervention. While additional data may be warranted for some stakeholders, these interventions hold promise as integral components of exercise-based prevention strategies for cardiovascular disease.    In this interview, Alexander Fanaroff, MD, MHS and Glenn A. Hirsch MD, MHS, FACC discuss results from the Be Active RCT.        Subscribe on Apple Podcasts |    

Be Active RCT: Gamification & Financial Incentives to Increase Physical Activity

 The VICTORION-INIATATE study demonstrated that initiating inclisiran, a highly potent lipid-lowering therapy, upon failure to achieve lipid targets with statins, yielded superior outcomes compared to standard care. This approach facilitated a greater proportion of patients in reaching LDL-C targets recommended by current guidelines. Presently, the conventional management of cholesterol disorders in the US routinely falls short of attaining treatment goals for the majority of patients.    In this interview, Michael J. Koren, MD, FACC, and C. Noel Bairey Merz, MD, FACC discuss results from the VICTORION-INITIATE randomized trial.  

Statin Intolerance, Inclisarin, and the VICTORION-INITIATE Trial

 Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment.     In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor  For Diabetic Cardiomyopathy.     Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

ARISE-HF Primary Results: Selective Aldose Reductase Inhibitor For Diabetic Cardiomyopathy

 It's becoming increasingly evident that alongside top-notch clinical expertise, the CV specialist of the future must be surrounded by a multi-talented, diverse team to provide optimal patient care. In addition, it is crucial that the clinician and CV organization engage in non-clinical competencies to enhance value for patients, the healthcare system, and society. MedAxiom and ACC collaborate synergistically toward achieving these goals.    In this interview, Jerry Blackwell MD, MBA, FACC and Joseph E. Marine MD, MBA, FACC, discuss The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape.         Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

The Future of Cardiology - Value-Based Care, Private Equity and the Practice Landscape

 Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk.     In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial.  

ACCEL Lite: Optimal Medical Therapy for Tricuspid Regurgitation: An Oxymoron?

Download our free app to listen on your phone